Epigenomic dysregulation in the bone marrow mesenchymal stem cells of acquired aplastic anemia patients: An in silico and in vitro study.
Scientists map molecular disruptions in bone marrow failure, uncovering multiple new targets for developing therapies.
Comprehensive epigenomic profiling of bone marrow mesenchymal stem cells from aplastic anemia patients identifies 713 disrupted regulators, including overexpression of SETD1A, MLL1, and EZH2 and downregulation of DNMT3A and KDM2B. This epigenomic landscape of the aplastic anemia niche reveals novel therapeutic targets for this immune-mediated bone marrow failure syndrome.
What the study was
- Study design
- bioinformatics analysis with in vitro experimental validation
- Population
- Aplastic anemia patients and healthy donors (BM-MSCs)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Molecular biology reports
Why it surfaced
Comprehensive epigenomic profiling of AA BM-MSCs identifies novel therapeutic targets for this immune-mediated bone marrow failure syndrome; directly relevant to T1 (hematologic) and T9 (rare disease) watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.